{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:37:56Z","timestamp":1792791476036,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001663","name":"Volkswagen Foundation","doi-asserted-by":"publisher","award":["90 087-1"],"award-info":[{"award-number":["90 087-1"]}],"id":[{"id":"10.13039\/501100001663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001663","name":"Volkswagen Foundation","doi-asserted-by":"publisher","award":["92 087"],"award-info":[{"award-number":["92 087"]}],"id":[{"id":"10.13039\/501100001663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["TRR241-A05"],"award-info":[{"award-number":["TRR241-A05"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["INST 335\/597-1"],"award-info":[{"award-number":["INST 335\/597-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["INST 335\/597-1"],"award-info":[{"award-number":["INST 335\/597-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TRR241-B01"],"award-info":[{"award-number":["TRR241-B01"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC1340"],"award-info":[{"award-number":["CRC1340"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC1449"],"award-info":[{"award-number":["CRC1449"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Passive immunization against SARS-CoV-2 limits viral burden and death from COVID-19; however, it poses a theoretical risk of disease exacerbation through antibody-dependent enhancement (ADE). ADE after anti-SARS-CoV2 antibody treatment has not been reported, and therefore the potential risk and promoting factors remain unknown.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 75-year-old female was admitted to the emergency room with recurrent, unexplained bruises and leukocytopenia, anemia, and thrombocytopenia. Evaluation of a bone marrow biopsy established the diagnosis of an acute promyelocytic leukemia (APL). SARS-CoV-2 RT-PCR testing of nasal and throat swabs on admission was negative. During the routine SARS-CoV-2 testing of inpatients, our patient tested positive for SARS-CoV-2 on day 14 after admission without typical COVID-19 symptoms. Due to disease- and therapy-related immunosuppression and advanced age conferring a high risk of progressing to severe COVID-19<jats:bold>,<\/jats:bold> casirivimab\u00a0and imdevimab were administered as a preemptive approach. The patient developed immune activation and cytokine release syndrome (CRS) occurring within four hours of preemptive anti-SARS-CoV2 antibody (casirivimab\/imdevimab) infusion. Immune activation and CRS were evidenced by a rapid increase in serum cytokines (IL-6, TNF\u03b1, IL-8, IL-10), acute respiratory insufficiency, and progressive acute respiratory distress syndrome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion and conclusion<\/jats:title>\n                <jats:p>The temporal relationship between therapeutic antibody administration and the rapid laboratory, radiological, and clinical deterioration suggests that CRS was an antibody-related adverse event, potentially exacerbated by APL treatment-mediated differentiation of leukemic blasts and promyelocytes. This case highlights the need for careful assessment of life-threatening adverse events after passive SARS-CoV-2 immunization, especially in the clinical context of patients with complex immune and hematological landscapes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07513-0","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T03:29:56Z","timestamp":1655090996000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Anti-SARS-CoV2 antibody-mediated cytokine release syndrome in a patient\u00a0with acute promyelocytic leukemia"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2946-8251","authenticated-orcid":false,"given":"Ahmed N.","family":"Hegazy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Kr\u00f6nke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Angermair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Weidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Treskatsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Siegmund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"key":"7513_CR1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu N, et al. A novel coronavirus from patients with pneumonia in China, 2019. New Engl J Med. 2020;382:727\u201333.","journal-title":"New Engl J Med"},{"key":"7513_CR2","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41564-020-00789-5","volume":"5","author":"WS Lee","year":"2020","unstructured":"Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol. 2020;5:1185\u201391.","journal-title":"Nat Microbiol"},{"key":"7513_CR3","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1126\/science.abb8925","volume":"368","author":"JB Moore","year":"2020","unstructured":"Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368:473\u20134.","journal-title":"Science"},{"key":"7513_CR4","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1126\/science.1185181","volume":"328","author":"W Dejnirattisai","year":"2010","unstructured":"Dejnirattisai W, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science. 2010;328:745\u20138.","journal-title":"Science"},{"key":"7513_CR5","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1056\/NEJMoa1800820","volume":"379","author":"S Sridhar","year":"2018","unstructured":"Sridhar S, et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med. 2018;379:327\u201340.","journal-title":"N Engl J Med"},{"key":"7513_CR6","doi-asserted-by":"publisher","first-page":"5752","DOI":"10.1038\/s41467-020-19568-1","volume":"11","author":"S Wang","year":"2020","unstructured":"Wang S, et al. Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys. Nat Commun. 2020;11:5752.","journal-title":"Nat Commun"},{"key":"7513_CR7","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa2035002","volume":"384","author":"DM Weinreich","year":"2020","unstructured":"Weinreich DM, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. New Engl J Med. 2020;384:238\u201351.","journal-title":"New Engl J Med"},{"key":"7513_CR8","unstructured":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Casirivimab and Imdevimab EUA Fact Sheet for Healthcare Providers. https:\/\/www.fda.gov\/media\/144468\/download"},{"key":"7513_CR9","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1126\/science.abd0827","volume":"369","author":"J Hansen","year":"2020","unstructured":"Hansen J, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020;369:1010\u20134.","journal-title":"Science"},{"key":"7513_CR10","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41577-021-00542-x","volume":"21","author":"PC Taylor","year":"2021","unstructured":"Taylor PC, et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021;21:382\u201393.","journal-title":"Nat Rev Immunol"},{"key":"7513_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1056\/NEJM199307153290307","volume":"329","author":"RP Warrell","year":"1993","unstructured":"Warrell RP, de Th\u00e9 H, Wang ZY, Degos L. Acute promyelocytic leukemia. N Engl J Med. 1993;329:177\u201389.","journal-title":"N Engl J Med"},{"key":"7513_CR12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/bjh.16151","volume":"187","author":"M Stahl","year":"2019","unstructured":"Stahl M, Tallman MS. Differentiation syndrome in acute promyelocytic leukaemia. Br J Haematol. 2019;187:157\u201362.","journal-title":"Br J Haematol"},{"key":"7513_CR13","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","volume":"383","author":"DC Fajgenbaum","year":"2020","unstructured":"Fajgenbaum DC, June CH. Cytokine storm. New Engl J Med. 2020;383:2255\u201373.","journal-title":"New Engl J Med"},{"key":"7513_CR14","doi-asserted-by":"publisher","first-page":"e290","DOI":"10.1016\/S2666-5247(20)30144-0","volume":"1","author":"B Schurink","year":"2020","unstructured":"Schurink B, et al. Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. The Lancet Microbe. 2020;1:e290\u20139.","journal-title":"The Lancet Microbe"},{"key":"7513_CR15","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","volume":"20","author":"MZ Tay","year":"2020","unstructured":"Tay MZ, Poh CM, R\u00e9nia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20:363\u201374.","journal-title":"Nat Rev Immunol"},{"key":"7513_CR16","doi-asserted-by":"publisher","first-page":"292","DOI":"10.7326\/0003-4819-117-4-292","volume":"117","author":"SR Frankel","year":"1992","unstructured":"Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP. The, \u201cretinoic acid syndrome\u201d in acute promyelocytic leukemia. Ann Intern Med. 1992;117:292\u20136.","journal-title":"Ann Intern Med"},{"key":"7513_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-020-6533-0","volume":"20","author":"LY de Almeida","year":"2020","unstructured":"de Almeida LY, et al. Interleukin-8 is not a predictive biomarker for the development of the acute promyelocytic leukemia differentiation syndrome. BMC Cancer. 2020;20:1\u20137.","journal-title":"BMC Cancer"},{"key":"7513_CR18","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/nrc2943","volume":"10","author":"H de Th\u00e9","year":"2010","unstructured":"de Th\u00e9 H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer. 2010;10:775\u201383.","journal-title":"Nat Rev Cancer"},{"key":"7513_CR19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0002-9343(91)90069-A","volume":"91","author":"T Calandra","year":"1991","unstructured":"Calandra T, Gerain J, Heumann D, Baumgartner JD, Glauser MP. High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. Am J Med. 1991;91:23\u20139.","journal-title":"Am J Med"},{"key":"7513_CR20","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","volume":"395","author":"N Chen","year":"2020","unstructured":"Chen N, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507\u201313.","journal-title":"Lancet"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07513-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07513-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07513-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T03:30:51Z","timestamp":1655091051000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07513-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7513"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07513-0","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,13]]},"assertion":[{"value":"10 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethics committee of Charit\u00e9-Universtit\u00e4tsmedizin Berlin (EA4\/117\/21).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient and included the consent to publish clinical information.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"B.S. has served as consultant for Abbvie, Arena, BMS, Boehringer, Celgene, Falk, Galapagos, Janssen, Lilly, Pfizer, Prometheus and Takeda and received speaker\u2019s fees from Abbvie, CED Service GmbH, Falk, Ferring, Janssen, Novartis, Pfizer, Takeda [payments were made to the institution]. A.N.H, J.K., T.S., S.S., S.T., S.A., U.K. declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"537"}}